cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cytomx Therapeutics Inc
13 own
13 watching
Current Price
$0.89
$0.02
(2.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
94.52M
52-Week High
52-Week High
5.85000
52-Week Low
52-Week Low
0.79000002
Average Volume
Average Volume
0.67M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization94.52M
icon52-Week High5.85000
icon52-Week Low0.79000002
iconAverage Volume0.67M
iconDividend Yield--
iconP/E Ratio--
What does the Cytomx Therapeutics Inc do?
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company s product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Read More
How much money does Cytomx Therapeutics Inc make?
News & Events about Cytomx Therapeutics Inc.
Globe Newswire
1 year ago
- Financing is expected to extend cash runway into the 2nd half of 2025 based on current operating plans, enabling the Company to reach multiple clinical milestones - - $30 million initial...
Zolmax
1 year ago
CytomX Therapeutics (NASDAQ:CTMX Get Rating) and Stoke Therapeutics (NASDAQ:STOK Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, ...
PR Newswire
1 year ago
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer PR Newswire VANCOUVER, British Columbia, March 24, 2023 FN Media Group Presents USA News Group News Commentary VANCOUVER...
Globe Newswire
2years ago
-Achievement of clinical candidate is the first in the multi-target collaboration and triggersa $5 million milestone payment to CytomX- -CytomX-retained US co-commercialization and economic rights for select programs- SOUTH SAN FRANCISCO, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics...
PR Newswire
2years ago
Thinking about buying stock in Spruce Biosciences, CytomX Therapeutics, Boxed, Mobile Global Esports, or Emergent Biosolutions? Thinking about buying stock in Spruce Biosciences, CytomX Therapeutics, Boxed, Mobile Global Esports, or Emergent Biosolutions? PR Newswire NEW YORK, Jan. 6, 2023 NEW...
Frequently Asked Questions
Frequently Asked Questions
What is Cytomx Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Cytomx Therapeutics Inc shares?
plus_minus_icon
How can I buy Cytomx Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Cytomx Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cytomx Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Cytomx Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Cytomx Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cytomx Therapeutics Inc?
plus_minus_icon
What percentage is Cytomx Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cytomx Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.89
$0.02
(2.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$34.46
$-0.92 (-2.60 %)
MacroGenics, Inc.
MacroGenics, Inc.
$3.23
$0.07 (2.22 %)
FibroGen Inc
FibroGen Inc
$0.51
$0.00 (0.59 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$114.91
$-0.72 (-0.62 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
$34.46
$-0.92 (-2.60 %)
MacroGenics, Inc.
MacroGenics, Inc.
$3.23
$0.07 (2.22 %)
FibroGen Inc
FibroGen Inc
$0.51
$0.00 (0.59 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$114.91
$-0.72 (-0.62 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00